Hims & Hers, Eli Lilly, and Amgen Innovate and Expand Access to Obesity Treatment: Market Leaders Drive Consumer-Driven Healthcare Evolution

The obesity treatment market is rapidly evolving, with companies like Hims & Hers Health, Inc. (HIMS), Eli Lilly and Company (LLY), and Amgen Inc. (AMGN) leading the charge in developing innovative solutions to help individuals manage their weight and improve their overall health. Hims & Hers Health, Inc., a renowned health and wellness platform, has prioritized weight loss as a key area of growth and innovation in its healthcare platform. The company recently introduced a six-month offer of Wegovy priced at $549 per month for eligible new customers, designed to improve affordability and sustained access to prescription weight loss medication. This initiative is part of Hims & Hers' broader strategy to make proven obesity treatments more connected and accessible through technology-driven, consumer-friendly healthcare delivery. The company's platform currently offers bundled access to all strengths of Wegovy with around-the-clock care, clinical support, and personalized nutrition coaching. This integrated approach, provided at a unified monthly price, is aimed at improving long-term health outcomes for people living with obesity. These efforts align with Hims & Hers' broader vision of consumer-centered healthcare that puts individuals at the center of care decisions and delivers a seamless patient experience across digital touchpoints. Eli Lilly and Company has advanced its leadership in the obesity treatment space with key developments in both injectables and oral therapies. This month, the company expanded access to all approved doses of Zepbound (tirzepatide) through its LillyDirect Self Pay Pharmacy Solutions platform, enhancing affordability and continuity of care for patients pursuing weight management. Complementing this, Eli Lilly's oral GLP-1 candidate, orforglipron, showed Phase 3 results with efficacy and safety comparable to injectable treatments, reinforcing the company's commitment to comprehensive obesity care. Amgen Inc. is actively advancing innovation in obesity care through differentiated, long-acting biologics. This month, the company unveiled full Phase 2 results for MariTide, a novel, monthly-dosed obesity treatment, showing up to 20% average weight loss and sustained cardiometabolic benefits over 52 weeks without a plateau. With improved tolerability from dose escalation, MariTide enters Phase 3 trials targeting obesity, Type 2 diabetes, cardiovascular disease, and sleep apnea, strengthening Amgen's position in the obesity therapeutics space. Shares of Hims & Hers have surged 73.6% year to date compared with the industry's growth of 18.2%. HIMS' forward 12-month P/S of 3.6X is lower than the industry's average of 5.9X, but higher than its five-year median of 2.6X. It carries a Value Score of C. The Zacks Consensus Estimate for HIMS' 2025 earnings per share suggests a 170.4% improvement from 2024. Hims & Hers stock currently carries a Zacks Rank #2 (Buy). In conclusion, the obesity treatment market is seeing significant innovation and growth as companies like Hims & Hers Health, Inc., Eli Lilly and Company, and Amgen Inc. develop new treatments and support systems to help individuals manage their weight and improve their overall health. With the increasing prevalence of obesity and its associated health risks, these companies are playing a crucial role in addressing this growing global health challenge.